ArticleFrontiers in oncology2026
Clinical and prognostic significance of high-endothelial venule density in regional lymph nodes of esophageal adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal adenocarcinoma (EAC) is associated with poor prognosis despite advances in multimodal treatment. High endothelial venules (HEVs) facilitate lymphocyte trafficking and are linked to anti-tumor immunity. While HEVs have shown prognostic relevance in esophageal squamous cell carcinoma and gastric cancer, their role in regional lymph nodes of EAC patients remains unclear. Methods: This retrospective study included 199 patients with EAC who underwent Ivor-Lewis esophagectomy between 2013 and 2021. Patients received perioperative chemotherapy (FLOT), neoadjuvant chemoradiotherapy (CROSS), or primary surgery. Tumor-free regional lymph nodes were immunohistochemically stained using the MECA-79 antibody to detect HEVs. Whole-slide images were digitally analyzed to quantify HEV density. Associations with clinicopathological parameters, treatment modality, therapy response, and survival outcomes were assessed. An exploratory analysis was performed in an additional cohort of 58 patients receiving adjuvant nivolumab therapy. Results: HEVs were detectable in regional lymph nodes across all treatment groups. HEV density was significantly higher in patients older than 60 years compared to younger patients (p = 0.001) and was independent of treatment modality, pathological response, T-stage, and N-stage. No association was observed between HEV density and response to neoadjuvant therapy. Dichotomization into MECA-low and MECA-high groups confirmed age as the primary determinant of HEV density classification. Kaplan-Meier analyses showed no significant differences in overall or progression-free survival between MECA-low and MECA-high patients in the primary cohort. In the adjuvant nivolumab cohort, MECA-high patients demonstrated a non-significant trend toward improved two-year overall survival (90% vs. 67%). Conclusions: HEV density in tumor-free regional lymph nodes of EAC patients is primarily age-dependent and independent of tumor stage, treatment response, and neoadjuvant therapy regimen. Although HEV density alone does not predict survival, observed trends in immunotherapy-treated patients suggest a potential modulatory role in immune responsiveness. These findings emphasize the importance of host-related immune architecture and support further investigation of lymph node-based immune biomarkers in EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.